Recent

% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

  • ajh8864@sbcglobal.net ajh8864 Jan 11, 2010 7:46 PM Flag

    FDA inspection

    Spencer has concluded it’s FDA inspection which was one of the last legacy “areas of concern” from the FDA. Additionally the Marlborough site was audited as you would expect being the “R&D” center for the endo surgery group and it too came out of the audit with minimal damage. So much work had gone into clearing this legacy hurdle that this may actually be one of the things that enables them to clear the warning letter. Congratulations are in order.

    Unfortunately clearing of the warning letter is already priced into this stock. Also clearing of the warning letter enables BSX to introduce new products, which it was already able to do by site or exception. Unfortunately, this company no longer holds the edge in next generation products; more like “next generation commodity”. With such a high debt to equity ratio and recent issuance of “senior stock” on the order of 2 billion to pay future debt, the likelihood of a favorable trend in the overall stock price remains low.

    Still a house of cards and a strong breeze in in the air……

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
BSX
16.07-0.55(-3.31%)Feb 8 4:01 PMEST